<DOC>
	<DOCNO>NCT00003682</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way make cancer cell stop divide stop grow die . Combining chemotherapy corticosteroid may effective treatment prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness methylprednisolone without doxorubicin treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Methylprednisolone With Without Doxorubicin Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effect weekly doxorubicin quality life patient metastatic , hormone-refractory , symptomatic prostate cancer . II . Determine contribution treatment control pain patient . III . Determine toxicity regimen patient . IV . Determine objective response biological observation patient treatment . V. Determine effect regimen survival patient . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . Arm I : Patients receive methylprednisolone IV weekly 3 month . Arm II : Patients receive methylprednisolone IV doxorubicin IV weekly 3 month . Quality life assess treatment , every 4 week treatment , every 3 month . Patients follow every 3 month . PROJECTED ACCRUAL : A total 160 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , symptomatic prostate cancer Appearance aggravation clinical symptom progression disease Bone pain OR Urethral compression OR 20 % decrease performance status Metastatic disease Localregional distant secondary tumor Documented radiologically scintigraphically Hormonerefractory define progression hormone treatment ( simple castration complete androgen blockage ) Progressive disease No urethral cervical stenosis Increase great 25 % prostatic volume endorectal echography No documentation PSA increase imagery Hormone castration verify testosterone le 0.5 ng/mL No history CNS metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : No specified Hematopoietic : Neutrophil count great 1500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 1.5 time normal Renal : Creatinine le 1.6 mg/dL Cardiovascular : Ventricular ejection fraction least 50 % Other : No contraindication anthracycline treatment No prior primary cancer except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Arm I : No concurrent chemotherapy Endocrine therapy : At least 1 month since prior hormone therapy , include estramustine , except LHRH agonist , continue Arm I : No concurrent estramustine Radiotherapy : At least 3 month since prior strontium 89 No concurrent strontium Surgery : See Disease Characteristics</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>